On March 27, 2026 the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of Sanofi’s subcutaneous formulation of Sarclisa (isatuximab). The new version will be delivered through an on‑body injector, making it the first anticancer treatment in the European Union to use this technology and the first multiple‑myeloma drug available in both on‑body injector and manual‑injection formats.
The approval would give Sanofi a significant competitive advantage in the multiple‑myeloma market, where Johnson & Johnson’s Darzalex currently holds a strong position. By offering a subcutaneous option, Sanofi can improve patient convenience and adherence, potentially increasing market share and enhancing the drug’s commercial appeal. The on‑body injector also aligns with the company’s broader oncology strategy, which focuses on difficult‑to‑treat cancers and innovative delivery methods.
The CHMP positive opinion is a key regulatory milestone; a final decision from the European Medicines Agency is expected in the coming months. Sanofi is also preparing a regulatory submission for the United States Food and Drug Administration, positioning the drug for a global launch.
Sanofi’s oncology portfolio is expanding rapidly. In addition to Sarclisa, the company has secured FDA Breakthrough Therapy designation for its Gaucher disease drug venglustat and entered a licensing agreement for the myelofibrosis drug rovadicitinib. The company’s focus on subcutaneous delivery is evident in other products such as Dupixent, further underscoring its commitment to patient‑centric therapies.
The EMA recommendation marks a pivotal step for Sanofi’s multiple‑myeloma strategy, potentially broadening its market reach and improving patient outcomes through a more convenient delivery system. The outcome also signals the company’s continued progress in bringing innovative oncology treatments to market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.